Annexon heads into its May 11 earnings report with short sellers at their most committed position in weeks — and options traders beginning to turn cautious.
Short interest is the clearest pre-earnings signal here. At nearly 15% of free float, it has climbed roughly 20% over the past month, a steady and deliberate build rather than a reactive spike. Days to cover stretch to nearly eight — meaning shorts would need more than a week and a half of average trading volume to exit. Cost to borrow remains subdued at 0.54%, but availability in the lending pool is ample, which means new shorts face little friction entering ahead of the print. The ORTEX short score has edged up to 62.3 from around 59.4 ten days ago, a quiet but consistent drift toward more bearish conviction.
Options tell a slightly different story. The put/call ratio has climbed to 0.27, roughly one standard deviation above its 20-day average — elevated relative to recent norms, but well below the 52-week high of 1.43. The move reflects modestly increased hedging demand, not outright fear. The stock itself is down about 6% on the week to $5.52, and off 5% over the past month, putting it well below the mean analyst price target of roughly $13.70. That gap is large enough to raise questions about target currency and timing, though the consensus direction — all Buy ratings across Chardan, Clear Street, Wells Fargo, HC Wainwright, and Needham — is unambiguously bullish.
The bull case rests on ANX005, which delivered a 10-point improvement in the MRC sum score versus standard of care — a recovery signal bulls argue is rarely seen with existing treatments. ANX007's early completion of Phase 3 enrollment and entry into the EMA's PRIME PDC pilot adds regulatory credibility to the geographic atrophy program. Bears focus on the cash burn: a $49.2 million net loss raises sustainability questions for a company still deep in development, with no approved product, no revenue, and meaningful regulatory risk on both sides of the Atlantic.
Institutional ownership offers a notable supporting data point. FMR and BlackRock both added to positions in recent months, and specialist healthcare funds — Redmile, BVF, Alerce, and Adage — are all meaningful holders with recent additions. That cluster of dedicated life-sciences money suggests the investment community sees binary upside in the pipeline rather than a terminal decline. Insider activity is mixed at low dollar values: a director bought modest amounts in March and April, while several C-suite executives sold small tranches in early March, likely scheduled disposals.
The print on May 11 is therefore less about the financial statements — a pre-revenue biotech's quarterly loss figures are almost beside the point — and more about whether management delivers new clinical or regulatory detail on ANX005 and ANX007 that shifts the probability calculus on approval timelines.
See the live data behind this article on ORTEX.
Open ANNX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
